LNTH:NSD-Lantheus Holdings Inc (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 107.98

Change

0.00 (0.00)%

Market Cap

USD 7.63B

Volume

0.58M

Analyst Target

USD 21.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-03 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
VTRS Viatris Inc

N/A

USD 13.87B
NBIX Neurocrine Biosciences Inc

N/A

USD 12.37B
ITCI Intracellular Th

N/A

USD 9.17B
ALKS Alkermes Plc

N/A

USD 4.28B
ALVO Alvotech

N/A

USD 3.93B
HCM HUTCHMED DRC

N/A

USD 3.18B
AMPH Amphastar P

N/A

USD 2.48B
SUPN Supernus Pharmaceuticals Inc

N/A

USD 1.93B
HROW Harrow Health Inc

N/A

USD 1.92B
KNSA Kiniksa Pharmaceuticals Ltd

N/A

USD 1.91B

ETFs Containing LNTH

WELL:PA HAN-GINS Indxx Healthcare.. 4.50 % 0.00 %

N/A

N/A
WELL:SW HAN-GINS Indxx Healthcare.. 4.50 % 0.00 %

N/A

N/A
MEDI Harbor Health Care ETF 4.36 % 0.00 %

N/A

USD 0.02B
GRPM Invesco S&P MidCap 400 GA.. 3.01 % 0.00 %

N/A

N/A
HLTH:AU VanEck Global Healthcare .. 2.11 % 0.00 %

N/A

USD 0.06B
XHE SPDR® S&P Health Care Eq.. 1.91 % 0.35 %

N/A

USD 0.21B
WELP:LSE HAN-GINS Indxx Healthcare.. 1.39 % 0.00 %

N/A

N/A
QWST 1.37 % 0.00 %

N/A

N/A
2B77:XETRA iShares Ageing Population.. 0.66 % 0.00 %

N/A

USD 0.50B
RTWO:LSE L&G Russell 2000 US Small.. 0.58 % 0.00 %

N/A

USD 0.15B
RTWP:LSE Legal & General UCITS ETF.. 0.58 % 0.00 %

N/A

USD 0.15B
ETLZ:XETRA L&G Russell 2000 US Small.. 0.58 % 0.00 %

N/A

USD 0.09B
VTWG Vanguard Russell 2000 Gro.. 0.55 % 0.20 %

N/A

USD 0.99B
GVLU Tidal ETF Trust 0.50 % 0.00 %

N/A

USD 0.17B
IWO iShares Russell 2000 Grow.. 0.00 % 0.24 %

N/A

N/A
RFG Invesco S&P MidCap 400® .. 0.00 % 0.35 %

N/A

N/A
VRTGX Vanguard Russell 2000 Gro.. 0.00 % 0.00 %

N/A

USD 1.19B
AGED:LSE iShares Ageing Population.. 0.00 % 0.00 %

N/A

N/A
AGES:LSE iShares IV Public Limited.. 0.00 % 0.00 %

N/A

N/A
WELL:LSE Hanetf Icav - Han-Gins He.. 0.00 % 0.00 %

N/A

N/A
W311:XETRA HAN-GINS Indxx Healthcare.. 0.00 % 0.00 %

N/A

USD 0.02B
2B77:F iShares Ageing Population.. 0.00 % 0.00 %

N/A

N/A
W311:F HAN-GINS Indxx Healthcare.. 0.00 % 0.00 %

N/A

USD 0.02B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 74.16% 56% F 78% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 74.16% 56% F 78% C+
Trailing 12 Months  
Capital Gain 67.88% 47% F 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 67.88% 47% F 75% C
Trailing 5 Years  
Capital Gain 409.34% 83% B 89% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 409.34% 83% B 89% A-
Average Annual (5 Year Horizon)  
Capital Gain 65.19% 85% B 90% A-
Dividend Return 65.19% 85% B 89% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 69.88% 49% F 28% F
Risk Adjusted Return 93.30% 99% N/A 95% A
Market Capitalization 7.63B 96% N/A 91% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.